PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared ...
2026-10-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
MILAN , Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with ...
2026-10-04T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. Paired ...
2026-10-03T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG , Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to ...
2026-10-03T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Chiron Medical Group's October "Safeguarding Breast Health With Heart" Campaign: Integrating Breast Health into Daily Life
"Safeguarding Breast Health With Heart" ...
2026-10-02T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
HONG KONG , Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) ...
2026-10-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system ...
2026-10-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager ...
2026-10-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
I Peace Selected as a TOP 10 Awardee for the "Top 10 Longevity Breakthrough Awards 2026"
PALO ALTO, Calif. , Oct. 2, 2026 /PRNewswire/ -- I Peace Inc., a biotech company pioneering induced pluripotent stem cell (iPS cell ) technologies for regenerative medicine and longevity, today announced ...
2026-10-02T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
ENA Members Choose Vanessa Gorman as 2027 President-elect
Secretary/treasurer, two board members also picked in annual election ...
2026-10-02T    Education   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.